三元生物(301206) - 2023 Q3 - 季度财报

Financial Performance - Revenue for Q3 2023 reached ¥115,878,873.28, an increase of 9.23% compared to the same period last year, but a decrease of 37.66% year-to-date[4] - Net profit attributable to shareholders for Q3 2023 was ¥8,355,862.63, down 73.87% year-on-year, and down 72.43% year-to-date[4] - Basic earnings per share for Q3 2023 was ¥0.04, a decrease of 75.00% compared to the same period last year[4] - The total operating revenue for the third quarter of 2023 was CNY 351,192,635.35, a decrease of 37.5% compared to CNY 563,363,651.68 in the same period last year[25] - The net profit for Q3 2023 was CNY 41,672,900.57, a decrease of 72.5% compared to CNY 151,155,941.78 in Q3 2022[26] - Operating profit for Q3 2023 was CNY 44,871,999.14, down 73.6% from CNY 169,888,387.28 in Q3 2022[26] - The total comprehensive income for Q3 2023 was CNY 41,672,900.57, a decrease of 72.5% from CNY 151,155,941.78 in the same quarter last year[27] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.21, compared to CNY 0.76 in Q3 2022[27] Assets and Liabilities - Total assets at the end of Q3 2023 were ¥4,755,601,460.68, a decrease of 2.35% from the end of the previous year[4] - The total assets as of September 30, 2023, were CNY 4,755,601,460.68, down from CNY 4,869,919,341.29 at the beginning of the year, a decrease of 2.3%[23] - The total liabilities decreased to CNY 234,780,503.70 from CNY 249,143,294.88, indicating a reduction of 5.8%[23] - The company's equity attributable to shareholders decreased to CNY 4,520,820,956.98 from CNY 4,620,776,046.41, a decline of 2.2%[23] Cash Flow - Cash flow from operating activities for the first nine months of 2023 was ¥21,942,222.52, down 75.73% year-on-year due to increased market competition[11] - Cash flow from operating activities generated a net amount of CNY 21,942,222.52, significantly lower than CNY 90,426,851.62 in the previous year[30] - The company's cash and cash equivalents decreased to CNY 117,966,133.78 from CNY 489,042,093.26 at the beginning of the year, representing a decline of 75.9%[21] - The company experienced a cash and cash equivalents net decrease of CNY -363,462,995.99, compared to an increase of CNY 256,890,519.32 in Q3 2022[30] - Total cash flow from investment activities was negative at CNY -251,828,518.11, compared to CNY -3,282,248,061.08 in the same period last year[30] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,770[13] - The total number of restricted shares at the beginning of the period was 92,946,000, with no shares released during the period, maintaining the same amount at the end[16] - 24,780,000 shares were released from restrictions for Shandong Luxin Qisheng Investment Management Co., Ltd. on February 10, 2023[16] - The company has a total of 12,852,000 restricted shares held by the shareholder Moxian, which were also released on February 10, 2023[16] - The management's locked shares include 2,160,000 shares for Li Dechun, with 25% of the total shares eligible for circulation each year during the tenure[16] - The shareholder Wang Meihua holds 2,745,395 shares, with 91,000 shares held through a regular account and 2,653,995 shares through a margin account[16] - The company reported a total of 5,400,000 restricted shares held by Shandong Kexin Venture Capital Co., Ltd., which were released on February 10, 2023[16] - The shareholder Zhang Yanjie has 2,206,697 restricted shares, all of which were released on February 10, 2023[16] - The total number of restricted shares held by the management team is subject to a 25% annual release during their tenure[16] - The company has a total of 1,137,258 restricted shares held by the shareholder Wang Meihua, which are also subject to the same release conditions[16] - The company has not disclosed any relationships or agreements among the top ten unrestricted shareholders[16] Operational Changes - The company decided to cancel the plan to use CNY 790 million of raised funds for permanent working capital supplementation due to lower than expected working capital needs[19] - The company held meetings to approve changes to its business scope and amendments to its articles of association to align with current operational needs[18] Other Income - Investment income for the first nine months of 2023 was ¥83,866,978.78, an increase of 39.56% compared to the same period last year[10] - Other income for the first nine months of 2023 was ¥821,692.01, a decrease of 87.55% year-on-year due to reduced government subsidies[10] Research and Development - Research and development expenses increased to CNY 36,626,985.64, up 14.5% from CNY 31,870,190.36 in the same period last year[26]